[Assessment of serum IgG activity correlation against cyclic citrullinated peptide antibodies, topoisomerase I and centromere proteins in Mexican patients with progressive systemic sclerosis].
OBJECTIVE
To evaluate sera titers for antibodies anti-cyclic citrullinated peptide and their correlation against sera levels of anti-topoisomerase I and anti-centromere antibodies in Mexican patients with systemic sclerosis.


METHODS
Consecutive outpatients with systemic sclerosis who attending to rheumatology clinic at a second level hospital facility. The antibodies anti-cyclic citrullinated peptide, anti-topoisomerase I and anti-centromere were determined by enzymatic immunoassay (ELISA).


METHODS
Spearman for correlation between numerical variables with nonparametric distribution. Fisher exact test or chi2 to compare proportions and Student t test for dimensional variables.


RESULTS
Thirty female patients were included; aged 53 +/- 13, the disease duration at the time of the study was 10 +/- 9. Twenty-three patients (77%) exhibited diffuse disease. Anti-centromere, anti-topoisomerase I, and anti-cyclic citrullinated peptide were detected in nine, nine and three patients respectively. The correlation analysis showed the independence of autoantibodies anti-centromere and anti-topoisomerase I with respect to the levels of anti-cyclic citrullinated peptide.


CONCLUSIONS
This study confirms the low frequency of anti-cyclic citrullinated peptide antibodies in patients with systemic sclerosis. A lack of correlation between autoantibodies considered as "mutually excluded" anti-topoisomerase I and anti-centromere, indicating that the analysis of the relevance for anti-cyclic citrullinated peptide in systemic sclerosis must include other clinical and serological variables.
Rocha-Muñoz
Alberto D
AD
Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, IMSS, Guadalajara, Jalisco, México.
González-López
Laura
L
Peguero-Gómez
Rebeca
R
Aguilar-Chávez
Erika A
EA
Villa-Manzano
Alberto I
AI
Corona-Sánchez
Esther
E
Galván-Méndez
Silvia
S
Presiado-Sánchez
Carmen
C
Vázquez-Jiménez
José C
JC
Riebeling
Carlos
C
Salazar-Páramo
Mario
M
Gámez-Nava
Jorge I
JI
Nava
Arnulfo
A
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology*; D002503:Centromere / Q000276:immunology*; D004264:DNA Topoisomerases, Type I / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000276:immunology; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology*; D045743:Scleroderma, Diffuse / Q000097:blood / Q000453:epidemiology / Q000276:immunology*
D001323:Autoantibodies; D001324:Autoantigens; D007074:Immunoglobulin G; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D004264:DNA Topoisomerases, Type I